PTCL cell lines with low IRF4 expression levels were found to be sensitive to lenalidomide, with the levels of IRF4 protein unchanged after lenalidomide administration [26]. The gene discussed is IRF4; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.